2006年6月8日,N Engl J Med杂志发表的一篇研究结果显示,与那些母亲在妊娠前3个月未暴露于血管紧张素转换酶抑制剂(ACEI)的婴儿相比,母亲在妊娠前3个月使用ACEI的婴儿,其发生重要先天性畸形的危险增加。但该研究中出生缺陷的病例数很少,且研究结果还未被重复。根据FDA批准的标 On June 8, 2006, a study published in the N Engl J Med magazine showed that mothers were pregnant during pregnancy compared with infants who had not been exposed to angiotensin-converting enzyme inhibitor (ACEI) during the first trimester of pregnancy Infants who used ACEI in the first 3 months had an increased risk of major congenital malformations. However, the number of birth defects in the study was small and the results were not repeated. According to the FDA approved standard